Business Context and Reporting Period
Company: AnaptysBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2018
Event: Entry into a Material Definitive Agreement for a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic operating results. Key financial figures related to the transaction include:
- Shares to be Issued: 2,200,000 shares of common stock.
- Public Offering Price: $94.46 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 330,000 shares.
- Estimated Net Proceeds: Approximately $197.1 million (after underwriting discounts, commissions, and estimated expenses, assuming no exercise of the option).
- Revenue/Profit/Cash Flow: The filing text does not provide current period revenue, profit, cash flow, or margin data.
- Debt/Liquidity: The filing text does not provide specific debt or liquidity ratios, though the proceeds are intended to fund operations.
Material Changes
The primary material change is the execution of an underwriting agreement with Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC, and Jefferies LLC. This represents a significant increase in equity capital compared to the prior period, intended to fund the company's pipeline.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: AnaptysBio intends to use the net proceeds for:
- New and ongoing research and development activities.
- Ongoing and planned clinical trials for etokimab and ANB019, including related manufacturing costs.
- Ongoing preclinical, discovery, and research programs.
- Working capital and other general corporate purposes.
Timing: The Offering is expected to close on September 28, 2018, subject to customary closing conditions.
Risks and Contingencies: The filing includes standard forward-looking statements cautioning that actual results may differ materially due to risks identified in the company's Form 10-K and 10-Q filings. These risks could materially and adversely affect results of operations and stock price.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected September 28, 2018).
- Confirm whether the underwriters exercise the 330,000 share over-allotment option.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification and market standoff provisions.
- Check subsequent filings for updates on the clinical trial progress for etokimab and ANB019 funded by these proceeds.
- Review the company's most recent Form 10-Q (filed August 7, 2018) for detailed liquidity and cash burn rates not included in this 8-K.